中西医结合治疗卵巢癌骨髓抑制临床诊疗专家共识  

Expert consensus on clinical diagnosis and treatment of myelosuppression in ovarian cancer with integrated Chinese and Western medicine

作　　者：李鹤[1] 茹丹 周艳[1] 张旭 丁忱欢[1] 俞超芹 张婷婷[3] 徐莲薇[4] 董莉[3] LI He;RU Dan;ZHOU Yan;ZHANG Xu;DING Chenhuan;YU Chaoqin;ZHANG Tingting;XU Lianwei;DONG Li(Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China;The First Affiliated Hospital of Naval Medical University(Changhai Hospital of Shanghai),Shanghai 200433,China;Yueyang Hospital of Integrated Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200437,China;Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China)

机构地区：[1]上海交通大学医学院附属仁济医院,上海200127 [2]海军军医大学第一附属医院(上海长海医院),上海200433 [3]上海中医药大学附属岳阳中西医结合医院,上海200437 [4]上海中医药大学附属龙华医院,上海200032

出　　处：《上海中医药杂志》2024年第S01期22-29,共8页Shanghai Journal of Traditional Chinese Medicine

基　　金：上海市卫健委进一步加快中医药传承创新发展三年行动计划项目(ZY[2021-2023]-0209-04)

摘　　要：卵巢癌常用的治疗方法是手术联合化学治疗(简称“化疗”),其中铂类与紫杉醇联合应用是一线化疗方案[1]。骨髓抑制是化疗后最常见的毒副反应之一,由于化疗药物抑制了细胞的快速分裂,致使骨髓中细胞活性降低,从而出现骨髓抑制[2],临床上主要以白细胞、红细胞、血小板及血红蛋白数量减少为主要表现,其中以白细胞数量减少较为多见,常伴随不同程度的贫血、出血及继发感染。

关 键 词：卵巢癌骨髓抑制 海派中医妇科 中西医结合 专家共识 

分 类 号：R737.31[医药卫生—肿瘤]